Download Files:
Reverse transcriptase-IN-1
$128 – $1,780
Products Details
Product Description
– Reverse transcriptase-IN-1 (Compound 12z), a diarylbenzopyrimidine (DABP) analogue, is a potent, orally active HIV-1 nonnucleoside reverse transcriptase inhibitor. Reverse transcriptase-IN-1 has antiviral activity with EC50 values of 3.4 nM, 4.3 nM and 3.6 nM for HIV-1 IIIB, E138K and K103N mutants, respectively. Reverse transcriptase-IN-1 also has an IC50of 13.7 nM against HIV-1 reverse transcriptase enzyme[1].
Web ID
– HY-130241
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– COVID-19-anti-virus
Molecular Formula
– C25H17N7O2
References
– [1]Han S, et al. Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles. ACS Infect Dis. 2019 Oct 24.
CAS Number
– 2380001-43-2
Molecular Weight
– 447.45
Compound Purity
– 98.08
SMILES
– N#CC1=CC=C(NC2=NC(NC3=C([N+]([O-])=O)C=C(/C=C/C#N)C=C3C)=C4C=CC=CC4=N2)C=C1
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– HIV
Isoform
– HIV-1
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
